Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Introduces its Diagnostic Products to Brazilian Market

SAN FRANCISCO, Nov. 14 – Myriad Genetics will market its predictive medicine products in Brazil through Sao Paulo-based Fleury Laboratories, the companies announced Wednesday.

The initial products marketed in Brazil from the Salt Lake City-based company will be cancer prediction kits, including ones to detect mutations for types of breast, skin, and colon cancer.

Financial details of the agreement were not disclosed.

Fleury Laboratories has 1,300 employees and 15 clinics throughout Brazil, according to the company.

Earlier in the month, Myriad reported a 22 percent rise in its revenue for the first quarter , from $10.8 million for the first quarter in 2000 to $13.2 million in 2001.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.